Chronic obstructive pulmonary disease: effects beyond the lungs
- PMID: 20305715
- PMCID: PMC2838746
- DOI: 10.1371/journal.pmed.1000220
Chronic obstructive pulmonary disease: effects beyond the lungs
Abstract
Peter Barnes discusses the growing epidemic of chronic obstructive pulmonary disease (COPD), especially in developing countries and among nonsmokers.
Conflict of interest statement
PJB is on the Editorial Board of
Figures

Similar articles
-
Other systemic manifestations of chronic obstructive pulmonary disease.Clin Chest Med. 2007 Sep;28(3):553-7, vi. doi: 10.1016/j.ccm.2007.06.005. Clin Chest Med. 2007. PMID: 17720043 Review.
-
[Smoking - part 3].Rev Assoc Med Bras (1992). 2010 Jul-Aug;56(4):384-8. doi: 10.1590/s0104-42302010000400005. Rev Assoc Med Bras (1992). 2010. PMID: 20835629 Review. Portuguese. No abstract available.
-
[Chronic obstructive pulmonary disease and associated illnesses].Ter Arkh. 2008;80(8):45-50. Ter Arkh. 2008. PMID: 18807540 Russian. No abstract available.
-
Chronic obstructive pulmonary disease and its comorbidities.Br J Hosp Med (Lond). 2011 Mar;72(3):137-45. doi: 10.12968/hmed.2011.72.3.137. Br J Hosp Med (Lond). 2011. PMID: 21475093 Review.
-
Chronic obstructive pulmonary disease with lung cancer and/or cardiovascular disease.Proc Am Thorac Soc. 2008 Dec 1;5(8):842-7. doi: 10.1513/pats.200807-075TH. Proc Am Thorac Soc. 2008. PMID: 19017739 Review.
Cited by
-
Exploring the association between magnesium deficiency and chronic obstructive pulmonary diseases in NHANES 2005-2018.Sci Rep. 2024 Oct 29;14(1):25981. doi: 10.1038/s41598-024-76374-1. Sci Rep. 2024. PMID: 39472459 Free PMC article.
-
Anti-Inflammatory Effects of Licania macrocarpa Cuatrec Methanol Extract Target Src- and TAK1-Mediated Pathways.Evid Based Complement Alternat Med. 2019 Sep 12;2019:4873870. doi: 10.1155/2019/4873870. eCollection 2019. Evid Based Complement Alternat Med. 2019. PMID: 31611922 Free PMC article.
-
Differences in clinical characteristics, management and short-term outcome between acute heart failure patients chronic obstructive pulmonary disease and those without this co-morbidity.Clin Res Cardiol. 2014 Sep;103(9):733-41. doi: 10.1007/s00392-014-0708-0. Epub 2014 Apr 10. Clin Res Cardiol. 2014. PMID: 24718849
-
[Pulmonary diseases in the elderly].Z Gerontol Geriatr. 2011 Aug;44(4):219-20. doi: 10.1007/s00391-011-0187-0. Z Gerontol Geriatr. 2011. PMID: 21842351 German. No abstract available.
-
Increased von Willebrand Factor Processing in COPD, Reflecting Lung Epithelium Damage, Is Associated with Emphysema, Exacerbations and Elevated Mortality Risk.Int J Chron Obstruct Pulmon Dis. 2020 Mar 9;15:543-552. doi: 10.2147/COPD.S235673. eCollection 2020. Int J Chron Obstruct Pulmon Dis. 2020. PMID: 32210548 Free PMC article.
References
-
- Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33:1165–1185. - PubMed
-
- Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension, and cardiovascular disease in chronic obstructive pulmonary disease. Eur Respir J. 2008;32:962–969. - PubMed
-
- Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical